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ABSTRACT
Objectives Nested qualitative studies within 
clinical trials provide the opportunity to 
better understand participant experiences 
of participation and identify areas where 
improved support is required. The purpose of 
this qualitative study is to describe the lived 
experiences of men with advanced prostate 
cancer participating in the TheraP trial; a 
randomised trial of 177Lu- PSMA-617 compared 
with cabazitaxel chemotherapy.
Methods Fifteen men with advanced prostate 
cancer were recruited from the TheraP clinical 
trial and interviewed at three time points during 
the trial. Interviews were inductively analysed 
using thematic analysis. This research paper 
reports the results from the baseline interview at 
commencement of the trial, focusing specifically 
on participants’ enrolment experiences.
Results Four themes were identified 
representing the lived experiences of men with 
advanced prostate cancer deciding to participate 
in the TheraP trial: (1) hoping to survive; (2) 
needing to feel informed; (3) choosing to 
participate and (4) being randomised. The 
process of deciding to enrol in a clinical trial is 
filled with indecision, emotional difficulties and 
focused on a desire to live.
Conclusions For men with advanced prostate 
cancer, the experience of deciding to enrol in 
a clinical trial is principally driven by a desire to 
survive but interlinked with the need to make 
an informed decision as participants in this 
study expressed a preference for allocation to 
the experimental arm. Men seeking to enrol in 
clinical trials of new prostate cancer treatments 
would benefit from improved informational and 
decision support.
Trial registration number NCT03392428, 
ANZUP1603.
BACKGROUND
Prostate cancer is the second most 
frequently diagnosed cancer and the sixth 
foremost cause of cancer death among 
men worldwide.1 Globally, an estimated 
358 000 men died from the disease in 
2018.2 Those living with advanced disease 
experience poor quality of life (QOL), 
greater psychological distress and unmet 
supportive care needs compared with 
men with localised disease.3 4 Men with 
advanced disease report high physical and 
psychosocial burdens from cancer and 
Key messages
What was already known?
 ► Clinical trials are an increasingly sought- 
after source of curative treatment for 
people with advanced cancer.
 ► There are gaps in the literature around 
how best to support people participating 
in trial who have advanced cancer.
What are the new findings?
 ► The experience of trial participation for 
men with advanced prostate cancer can 
be represented by ‘hoping to survive’, 
‘needing to feel informed’, ‘choosing to 
participate’ and ‘being randomised’.
 ► The process of deciding to enrol in a 
clinical trial if filled with indecision, 
emotional difficulties and focused on a 
desire to live.
What is their significance?
a. Clinical: This is the first study to articulate 
the experience of men with advanced 
prostate cancer who participate in a trial.
b. Research: Implications from this study 
highlight the need for tailored information 
and improved psychological support 
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treatment side effects including pain, sarcopenia, dete-
riorating bone health, cognitive and sexual dysfunc-
tion, fatigue, hot flushes, urinary incontinence, bowel 
changes, increased fat mass and body image alterations 
and psychosocial distress.5–10 It is essential new treat-
ments extend life without increasing health- related 
burdens for men with advanced prostate cancer.
The search for new effective and acceptable treat-
ments is of interest to cancer survivors the world over 
amidst a significant uplift in global trial registrations 
from 1255 in 2000 to 348 177 studies in 2020.11 As 
of August 2020, a record 52 347 trials were registered 
actively recruiting participants11 yet barriers to partic-
ipation have continued. Although around 70% of 
people living with cancer are willing to participate in 
clinical trials,12 research suggests fewer than 5% ulti-
mately enrol.13 14
For individuals with advanced prostate cancer, the 
opportunity to enrol in a clinical trial could provide 
hope,15, 16 specialist care15 and improve health.17 
TheraP is an Australian multisite randomised phase 
II, non- blinded trial of 177Lu- PSMA-617 (Lu- PSMA) 
theranostics versus cabazitaxel chemotherapy, a stan-
dard treatment, in men with progressive metastatic 
castration resistance prostate cancer.18 Lu- PSMA is a 
radiolabelled small molecule that binds to prostate- 
specific membrane antigen (PSMA) enabling delivery 
of targeted radiation to sites of prostate cancer metas-
tases.19, 20 Results showed that Lu- PSMA-617 is more 
active with higher PSA responses, more radiographic 
responses and longer progression- free survival.21 It 
also demonstrated less adverse events and improve-
ments in some patient- reported outcome domains.
With individuals seeking clinical trials as a poten-
tial source of curative treatment, it is necessary to 
understand the experience and supportive needs of 
patients deciding to participate in a cancer trial.22 
Embedding qualitative studies within clinical trials 
have been recognised as highly effective in influencing 
clinical trials design23 and has the potential to improve 
recruitment, retention and trial conduct, assist trialists 
sensitivity towards participants and guide researchers 
towards implementing more effective interventions 
in future trials, however it is infrequently used.24 The 
use of qualitative research may enable better under-
standing of the holistic illness experience of men with 
progressive cancer.25
Few clinical trials have nested qualitative studies as 
a mechanism for exploring the experience of partic-
ipants in trials of advanced cancer treatments and 
none in men with advanced prostate cancer deciding 
to enrol and participate in a clinical trial. Accordingly, 
we undertook a qualitative study describing the lived 
experiences of men with advanced prostate cancer 
enrolled in the TheraP clinical trial. In this paper, we 
report participant motivations, perspectives and expe-
riences of deciding to enrol in the TheraP trial.
METHODS
Aim and objectives
The aim of this nested qualitative study is to describe 
the lived experiences of men with advanced prostate 
cancer participating in the TheraP trial; a randomised 
trial of 177Lu- PSMA-617 compared with cabazitaxel 
chemotherapy. It is anticipated that the unique context 
of clinical trial enrolment among men with advanced 
prostate cancer elicits similarly unique needs additional 
to those already required by these men. To this end, 
the objective of this study is to identify and describe 
the lived experience of deciding to enrol in a clinical 
trial as well as the factors that inform the decision to 
enrol in a clinical trial among men with advanced pros-
tate cancer.
Broad eligibility criteria for TheraP clinical trial
Men with metastatic castration resistant pros-
tate cancer considered to receive cabazitaxel as 
the following applicable standard treatment were 
recruited for the TheraP clinical trial. Participants 
required a performance status of 0–2 according to 
the Eastern Cooperative Oncology Group and suffi-
cient haematological, renal and liver activity. Previous 
treatment with androgen receptor- directed therapy 
was permitted. PET- CT scans including gallium-68 
[68Ga] Ga- PSMA-11 and 2- flourine-18[18F] fluoro-2- 
deoxy- D- glucose (FDG) were completed in which the 
eligibility criteria included PSMA- positive disease and 
no sites of metastatic disease with conflicting FDG- 
positive and PSMA- negative findings.26
Participants
Fifteen men with advanced prostate cancer were 
recruited from Peter MacCallum Cancer Centre 
(Melbourne) and Royal Brisbane and Women’s 
Hospital (Brisbane) participating in the TheraP clinical 
trial of 177Lu- PSMA versus cabazitaxel.21 In addition 
to criteria for TheraP trial recruitment, participants 
in QualTheraP were required to: (1) read and speak 
English; (2) have no history of head injury, dementia 
or psychiatric illness and (3) have phone access.
Procedure
Eligible participants were approached by trial clini-
cians and provided with an information brochure 
about the QualTheraP substudy and a ‘permission to 
contact’ form. The invitation process was designed to 
explain the research in more detail, assess the partic-
ipants interest in participating, determine eligibility 
and make an appointment to commence the inter-
view process. Recruitment to the QualTheraP study 
commenced 3 April 2019 and ceased 7 January 2020.
All patients were interviewed via telephone, the 
most convenient form of communication for partic-
ipants. All participants provided written informed 
consent. Additional verbal consent was confirmed 
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were scheduled prospectively at three time points: 
after enrolment but prerandomisation as a baseline 
interview (commencement of the trial), midpoint of 
treatment at 11 weeks and completion of treatment at 
23 weeks, with an additional follow- up interview, to 
explore longitudinal experiences of the main TheraP 
trial.
Interviews at prerandomisation were carried out 
for this study by two researchers (BV, NR), who were 
previously unknown to participants. An interview 
protocol was used (online supplemental table 1), 
which covered motivations for trial enrolment, under-
standing of trial processes and supportive care needs. 
The protocol, study research questions and qualitative 
semi- structured interview method, encouraged partici-
pants to speak freely and cultivate their own narratives 
about the trial journey more broadly. Interviews lasted 
approximately 1 hour. The interviews were audio- 
recorded, transcribed verbatim and anonymised. This 
research paper reports results from the baseline inter-
view at commencement of the trial. The final number 
of recruited participants for the initial assessment is 
shown in figure 1. The participants’ demographic data 
are shown in online supplemental table 2.
Data analysis
Following this methodology, thematic analysis 
was performed with results presented as narrative 
synthesis. The transcripts of interviews were coded 
and categorised (BV). Researchers (BV, NR) analysed 
the transcripts for common themes of trial partic-
ipants’ experiences. Coders used the approach to 
thematic analysis by Braun and Clarke27 and a prelimi-
nary coding schema was created in NVIVO V.12 (QSR 
International 2018) by coding all transcripts with two 
additional members of the study team reviewing theme 
categorisation to improve the reliability and validity of 
the data. Reporting of data conforms with the Criteria 
for Reporting Qualitative Studies guidelines.28
RESULTS
Four themes were identified representing the lived 
experiences of men with advanced prostate cancer 
deciding to participate in the TheraP trial: (1) hoping 
to survive; (2) needing to feel informed; (3) choosing 
to participate and (4) being randomised. Selected 
quotations are shown in online supplemental table 3 
to represent the identified themes and participants’ 
perspectives.
Hoping to survive
Participants reported becoming aware of the TheraP 
trial in the context of their advancing cancer, exten-
sive side effects from cancer and related treatment, 
desire to find an effective treatment for their disease 
and to live. Amidst a variety of reported treatments 
such as hormone therapy, chemotherapy, radia-
tion therapy and radical prostatectomy, participants 
reported a sense of deteriorating health as the burden 
from symptoms such as pain, fatigue, urinary incon-
tinence, haematuria, loss of appetite and weight and 
sexual dysfunction worsened. Sensing their deteriora-
tion, participants experienced psychosocial burdens 
such as stress, anxiety, uncertainty and fear in addition 
to a feeling of hopelessness that previous treatments 
had failed to arrest their disease and left them with 
debilitating side effects such as urinary incontinence 
and haematuria. Most described being told by their 
oncologist that due to their disease advancing, there 
were only limited treatment options available to them. 
Participants described their desire to live and urgently 
seeking alternative treatment to extend and improve 
their QOL. In the context of limited treatment options, 
participants expressed newfound hope of obtaining 
benefit from improving, extending or saving their life 
by receiving Lu- PSMA:
So, we are just going to run out of treatment to keep 
me going you know. At some point all of this stuff 
we’ve got is going to stop working and you know, we 
are going to hit end of the road sort of thing. (ID011)
I’m on the lookout for, and hopeful that there might 
be various things which can extend it (life). (ID004)
Needing to feel informed
Contemporaneous to participants’ hope for improved 
survival was their search for information on available 
treatment options and the likelihood of these being life- 
extending for them or reducing debilitating symptoms. 
Participants referred to using a variety of mechanisms 
to source the best information about new treatments 
such as internet search engines, forums and support 
groups to identify possible treatment options in clin-
ical trials and take this information to their treating 
oncologist for discussion. Many reported being aware 
Figure 1 Study flow diagram. *Reasons for withdrawal 
include failing kidneys (n=1), the mutual agreement between 
physician and patient not to continue (n=1), a desire to end 
treatment and be placed into palliative care (n=2) and death 
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of the experimental Lu- PSMA treatment and expressed 
optimism and hope about its effectiveness.
What interested me was the fact that it seemed to be 
giving the best results from anything that we’d heard 
about. We’d more often spoken to people who’d 
been on it both overseas and here who’d had it and 
it extended their life by some period of time. And 
so—and that was, of course, the ultimate game—
ultimate aim, I guess, of any of these things that 
you’re on… whatever it is, is to provide a satisfactory 
sort extension of your life, I guess. (ID006)
The interaction between patient and physician was 
essential to resolving their uncertainty by evaluating 
whether trial treatments might be effective for their 
disease and to gain access to trials.
He (oncologist) said ‘look maybe we can look at a 
trial that might attack it in a different way and give 
your body a bit of a chance to recover more’. That 
really interested me because I was really struggling so 
then he sat me down and gave me some information 
about it. (ID011)
During trial recruitment, participants reported diffi-
culty in comprehending trial information and processes 
as written materials were complex and voluminous. 
As a mechanism for understanding the trial they 
were enrolled in, participants reported searching the 
internet to help comprehend the written materials they 
received, and the verbal information communicated to 
them. Participants also expressed their preference for 
more succinct trial information including the trial aim, 
side effects of treatment, routes of therapeutic admin-
istration and an estimate of the duration of treatment 
effectiveness for their disease.
So, if it just comes back to the normal man’s sort 
of language, I think it would be a lot easier for a lot 
of people to understand. I understand a lot of these 
chemotherapies and that have long names and all of 
the bits and pieces to it, but if they could explain it a 
little bit simpler. (ID003)
I don’t like getting too much information. I just want 
the bare bones and that’s really… so for me, that 
was enough. It told me the side effects, it told me 
the possible routes, it told, and you know, it won’t 
hold the cancer for huge amounts of periods, it will 
only be sort of up to 12 to 18 months at the most. 
(ID011)
Participants commonly reported difficulty relaying 
information received from treating health profes-
sionals and trialists relevant to their family members. 
Consequently, participants sourced further infor-
mation about the trial with their family members, 
kept their own records, recorded consultations and 
obtained further information from support groups on 
social media.
I did research more, but I thought the notes regarding 
the trial were very comprehensive and yeah, they were 
good, they gave me a, certainly a good understanding, 
but then, as I say, I did read up about the different 
treatments and, you know, did a bit more research 
so, I had a bit more thorough information, certainly, 
certainly the trial documentation was well presented. 
(ID014)
Choosing to participate
Participants reported a range of motivations they 
felt were key determinants in choosing whether to 
participate in the TheraP trial, including personal 
gain, altruism, recommendation from a health profes-
sional and encouragement from family and/or friends. 
For personal gain, although the desire for a cure was 
a primary motivator, so too was the possibility of 
obtaining precise insights into their disease status as 
they perceived clinical trials provided a high standard 
of care at no further personal expense.
Well the first thing of course is totally for my benefit. 
(ID005)
I decided I would apply for a trial, one of the, one 
of things I was very keen on, was that…there would 
be some thorough scans done, and we would then 
have a very good understanding of where my illness 
currently sits. (ID014)
It [trial- based care] was just sort of like business 
as usual but with perhaps more thorough screening 
during the process, that I would have got from my 
oncologist because, you know, a lot of these scans 
that are being done for example, are expensive, if 
you’ve got to pay for them yourself, and so, that was 
on offer. (ID014)
Participating for altruistic purposes was justified using 
reasons such as assisting in advancing clinical research, 
enhancing cancer care for fellow cancer survivors or 
subsequent generations of their family should they be 
diagnosed with the disease. In the case of the latter, 
rationalising participation as a positive was associ-
ated with encouragement and support from family 
members:
The second motivation is that if it extends the 
knowledge of human medicine and condition… 
if I can do something to, for my future, for my 
grandchildren I’m happy to do that. I can’t see any 
use in not being around to enjoy them and enjoy the 
grandchildren and have a happy life. I’ve got a lot of 
people who love me and don’t want to see me go. 
(ID005)
Why I’m happy to do the trials because we, firstly we 
feel people have done this for me, to get me this far 
down and now it’s my turn to step up and be there 
for the next lot of people who have got the fight in 
front of them. (ID011)
Being randomised
For most participants, being randomised to a trial 
treatment was difficult to comprehend and/or accept 
as allocation to their desired treatment was seen to be 
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in getting to the point of deciding to participate 
in a trial suddenly felt compromised by the uncer-
tainty introduced by potential randomisation to a 
non- preferred treatment. Additionally, the certainty 
desired by participants in seeking access to promising 
new treatments (such as 177Lu- PSMA-617) and able to 
help them live longer or with fewer symptoms in trials 
felt at risk when confronted with the uncertainty of 
randomisation.
Participants were eager to receive the new experi-
mental treatment 177Lu- PSMA-617. Due to cancer 
progression after previous treatment, limited treat-
ment options and feeling a sense of hope from trial 
information, many participants were very optimistic 
about the prospect of receiving a good outcome from 
177Lu- PSMA-617 (despite not knowing whether they 
would receive it). The perceived benefits and odds 
of receiving the experimental treatment seemed to 
outweigh the burden of the randomisation process. 
For some, their desperation to receive 177Lu- PSMA 
extended to the point where they were willing to 
leave the trial and pay for the experimental treatment 
outside of the trial if not allocated to that treatment 
arm. This included obtaining a second mortgage, using 
their superannuation funds, and organising financial 
support from family and friends.
So that, and then she [health professional] said to me 
this is on but its random, you’ve got 50% chance of 
getting into the trial and I hoped and hoped. (ID010)
I mean, I guess if worse came to worse, we’d probably 
hock the house and if someone said, ‘look, you’ll get 5 
years extra out of Lutetium’, I guess we’d be prepared 
to hock the house to do that, I guess. (ID006)
There are no strings you could pull or anything to 
get it, so you’ve just got to wait for the dice to roll. 
(ID010)
DISCUSSION
Our findings show the experience of men enrolling 
in TheraP trial is represented by the four themes 
of: ‘hoping to survive’; ‘needing to feel informed’; 
‘choosing to participate’ and ‘being randomised’ with 
results suggesting men seeking to enrol in clinical trials 
of new prostate cancer treatments would benefit from 
improved informational and decision support.
First, we observed an unusual phenomenon in this 
study with all participants expressing a negative view 
at the prospect of receiving further chemotherapy and 
a strong preference for, or favourable perception of, 
177Lu- PSMA-617 despite it being a new, unproven 
experimental treatment. This view is particularly 
remarkable given cabazitaxel is a proven treatment 
for men with advanced prostate cancer,29 although 
anticipatory fears about chemotherapy are previously 
reported in the literature.30 Additionally, among men 
who were randomly assigned to cabazitaxel in the 
TheraP trial, 14 (14%) withdrew owing to clinical 
preference and 1 (1%) withdrew owing to clinical 
preference and 1 (1%) man met an exclusion criterion 
(thrombocytopenia) after initial eligibility.
There are several explanations for such strong posi-
tive views towards the experimental arm therapy 
including that 177Lu- PSMA treatment was already 
available as a ‘fee- for- service’ from private providers 
where usually, unapproved therapies would not be 
accessible outside a clinical trial.31 Moreover, there 
were published data and publicly available experiences 
shared on popular survivorship forums prior to the 
TheraP trial commencement.31-33 It is also possible 
that given 12 men participating in this study had 
already received docetaxel chemotherapy, emphatic 
expressions of hope around the ‘new’ treatment may 
have emanated from both awareness of published data 
and experiences of others receiving 177Lu- PSMA, and 
a desire to avoid further chemotherapy treatment and 
its side effects.
The availability of Lu- PSMA as a fee for service 
and the peer- to- peer sharing of treatment experiences 
on survivorship forums has implications for clini-
cians and researchers working with an increasingly 
digitally literate population of prostate cancer survi-
vors.34 With limitations in the quality of peer- to- peer 
anecdotal evidence shared online and inaccuracies in 
internet- based information on prostate cancer treat-
ments,35 clinical trialists and clinicians should adopt a 
communication approach to clarify individual patient 
motivations for joining a trial, provide relevant and 
personalised trial information to prospective partic-
ipants and discuss their expectations of outcomes to 
promote shared decision- making.36-38
Men in our study reported the need to feel informed 
about the trial and a need for more user- friendly, 
simpler, succinct trial information. A focus for 
improving the trial experience must include reducing 
information overload by providing effective trial 
decision support tools. Recent evidence suggests the 
‘high stakes’ nature of clinical trial information and 
discussion at recruitment may be psychologically chal-
lenging and cognitively complex to individuals, influ-
encing their decision to accept trial participation.39-41 
Although cancer information overload among survi-
vors is a well- described phenomenon in the literature, 
overloading an individual with information does not 
appears to be associated with the decision to enrol 
in a clinical trial.39 However, reducing the feeling of 
information overload is associated with a positive 
attitude towards participating in clinical trials with a 
recent study reporting that simple, personalised and 
interactive messages improved individuals’ attitudes 
and informed consent as part of the trial and lowered 
feelings of cancer information overload.42
Interventions catering to the communication pref-
erences of participants and promoting opportunities 
for feedback about the nature of trial participation 
are necessary, particularly where such interventions 
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clinicians, trialists and participants.42, 43 Although 
previous review- level evidence shows a lack of 
effective decision support in the context of clin-
ical trials,44 a recent intervention was reported to 
be effective where information was delivered in a 
multimodal interactive format to promote shared 
decision- making.45, 46
Strengths and limitations
This study addresses a key gap in the literature in 
understanding the experiences of men with advanced 
prostate cancer in a clinical trial. Strengths of this 
study include being nested within the trial, obtaining 
perspectives and experiences of deciding whether to 
participate in a trial postenrolment, but prerandomi-
sation reduced the chance of participants rational-
ising the result of their randomisation in a positive or 
negative manner. Limitations of this study are that it 
does not include patients who ultimately chose not 
to participate in the trial, additionally that we were 
unable to interview partners or family of men deciding 
to enrol to the extent of identifying the role of family 
in making a decision about whether to participate in a 
clinical trial.
CONCLUSION
This study provides an insight into patient experience 
of a novel treatment for advanced prostate cancer. 
Our results indicate that participants preferred to be 
randomised to the experimental arm despite a lack of 
evidence about effectiveness. Furthermore, we iden-
tified that uncertainty about survival, the advanced 
disease context and the subsequent experience of 
deciding to enrol in a clinical trial interlinks with the 
need for information and support surrounding the 
decision whether to enrol in a clinical trial. For these 
men, there is a desire for simple, effective and engaging 
trial information allowing them to judge whether 
a clinical trial may offer the chance to achieve their 
treatment- related goals. Further research is required 
to implement interventions that promote informed 
consent and shared decision- making. Please see online 
supplemental file 2 for references 16–46.
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